flupenthixol has been researched along with Nicotine Addiction in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grieder, TE; Sellings, LH; Siu, EC; Ting-A-Kee, R; Tyndale, RF; van der Kooy, D; Vargas-Perez, H | 1 |
| Laviolette, SR; van der Kooy, D | 1 |
| Wilkins, JN | 1 |
3 other study(ies) available for flupenthixol and Nicotine Addiction
| Article | Year |
|---|---|
Dopaminergic signaling mediates the motivational response underlying the opponent process to chronic but not acute nicotine.
Topics: Analysis of Variance; Animals; Avoidance Learning; Behavior, Animal; Conditioning, Operant; Disease Models, Animal; Dopamine; Dopamine Antagonists; Drug Administration Schedule; Flupenthixol; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Motivation; Nicotine; Nicotinic Agonists; Rats; Rats, Wistar; Reaction Time; Receptors, Dopamine D2; Reward; Signal Transduction; Tobacco Use Disorder | 2010 |
Blockade of mesolimbic dopamine transmission dramatically increases sensitivity to the rewarding effects of nicotine in the ventral tegmental area.
Topics: Animals; Avoidance Learning; Conditioning, Psychological; Dopamine; Dopamine Antagonists; Flupenthixol; Limbic System; Male; Motivation; Nicotine; Nicotinic Agonists; Phenotype; Rats; Rats, Wistar; Receptors, Dopamine; Reward; Synaptic Transmission; Tobacco Use Disorder; Ventral Tegmental Area | 2003 |
Pharmacotherapy of schizophrenia patients with comorbid substance abuse.
Topics: Alcoholism; Antipsychotic Agents; Cocaine; Flupenthixol; Humans; Imipramine; Marijuana Abuse; Opioid-Related Disorders; Schizophrenia; Self Medication; Substance-Related Disorders; Tobacco Use Disorder | 1997 |